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Abstract
Background: Health economic analysis traditionally relies on patient derived questionnaire data, routine datasets,
and outcomes data from experimental randomised control trials and other clinical studies, which are generally
used as stand-alone datasets. Herein, we outline the potential implications of linking these datasets to give one
single joined up data-resource for health economic analysis.
Method: The linkage of individual level data from questionnaires with routinely-captured health care data allows
the entire patient journey to be mapped both retrospectively and prospectively. We illustrate this with examples
from an Ankylosing Spondylitis (AS) cohort by linking patient reported study dataset with the routinely collected
general practitioner (GP) data, inpatient (IP) and outpatient (OP) datasets, and Accident and Emergency department
data in Wales. The linked data system allows: (1) retrospective and prospective tracking of patient pathways
through multiple healthcare facilities; (2) validation and clarification of patient-reported recall data, complementing
the questionnaire/routine data information; (3) obtaining objective measure of the costs of chronic conditions for a
longer time horizon, and during the pre-diagnosis period; (4) assessment of health service usage, referral histories,
prescribed drugs and co-morbidities; and (5) profiling and stratification of patients relating to disease manifestation,
lifestyles, co-morbidities, and associated costs.
Results: Using the GP data system we tracked about 183 AS patients retrospectively and prospectively from the
date of questionnaire completion to gather the following information: (a) number of GP events; (b) presence of a
GP ‘drug’ read codes; and (c) the presence of a GP ‘diagnostic’ read codes. We tracked 236 and 296 AS patients
through the OP and IP data systems respectively to count the number of OP visits; and IP admissions and duration.
The results are presented under several patient stratification schemes based on disease severity, functions, age, sex,
and the onset of disease symptoms.
Conclusion: The linked data system offers unique opportunities for enhanced longitudinal health economic
analysis not possible through the use of traditional isolated datasets. Additionally, this data linkage provides
important information to improve diagnostic and referral pathways, and thus helps maximise clinical efficiency and
efficiency in the use of resources.
Background
Health service research have tended to rely on data gen-
erated from randomised controlled trials (RCT), obser-
vational studies based on patient derived questionnaire
data, and routinely assembled data abstracted from the
primary and secondary care patient record - popularly
known as routine data [1]. Data generated from these
three routes are predominantly used as stand-alone
datasets, and alongside non-health data such as demo-
graphic and geographical data [1,2]. The health sector
analyses are enriched when the patient-level data gener-
ated from these different sources are linked. Many
countries worldwide already routinely capture health
care data that can be used for such purposes. For exam-
ple, the Scottish Morbidity Linked Dataset which
encompasses Scottish Health Survey records, linked to
NHS acute and psychiatric hospital records, cancer, and
death registrations provides powerful research database
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record linkage between a hospital database and the
French national mortality database offers new prospects
for large prognostic studies based on hospital data [3];
and in Norway, the Medical Birth Registry of Norway is
routinely linked with the Central Population Register,
and can be linked with the other central health registers.
This paper discusses the potential methodological
advantages in the conduct of health economics analyses
using patient-derived questionnaire data linked with
routinely collected information and secondary care clini-
cal datasets available in Wales, United Kingdom, with
examples from a research cohort.
Methods
SAIL databank
In order to realise the potential of electronically-held
routinely collected information to conduct and support
health-related research, the Health Information Research
Unit (HIRU) at the College of Medicine at Swansea Uni-
versity, as part of the Welsh Assembly Government’s
commitment to the UK Clinical Research Collaboration
(UKCRC), has set up the Secure Anonymised Informa-
tion Linkage (SAIL) databank [4,5]. The SAIL databank
brings together and links a wide range of person-based
data. SAIL utilises a split-file approach to anonymisation
to overcome issues of confidentiality and disclosure in
health-related data warehousing by creating personal-
level unique and encrypted identifiers for merging infor-
mation from various sources [4,5]. The range of comple-
mentary sets of data includes clinical data from
rheumatologists, existing routinely collected datasets
such as the General Practice (GP) records, outpatient
(OP) clinical data, inpatient (IP) episodes, accident and
emergency (A&E) department, pathology data, NHS
administrative register, breast and cervical cancer
screening data, all Wales injury surveillance system, all
Wales perinatal survey, congenital anomaly register and
information service, birth and death data from the
Office for National Statistics, and social services
databases.
Data linkage
HIRU uses the MACRAL (Matching Algorithm for Con-
sistent Results in Anonymised Linkage) algorithm to
create encrypted Anonymised Linking Field (ALF) for
each individual [4]. The ALFs are mainly created based
on the patient’s NHS number; and if the NHS number
is absent in a dataset, a mixture of other identifying
variables like forename, surname, gender, postcode of
residence, and date of birth are used for probabilistic
matching, while maintaining complete anonymity for
the end users [4]. This linkage allows us to follow the
patient pathway through the NHS system both
retrospectively and prospectively from a reference date
(e.g. questionnaire completion date). This system also
allows linkage of data collected through patient ques-
tionnaires with other routinely collected datasets in the
SAIL system.
Data linkage with PAS cohort
As part of the Medical Research Council (MRC) Patient
Research Cohort Initiative, a cohort of people with
ankylosing spondylitis (AS),i . e .t h eW e l s hp o p u l a t i o n -
based ankylosing spondylitis (PAS) cohort, has been
developed using data collected from patient completed
questionnaires linked with routine data [6]. The study
aims to recruit 1000 AS patients living in Wales and
currently about 500+ AS patients are participating. This
study has ethical approval from the London Multi-cen-
tre Research Ethics committee and the written consent
of participants was obtained according to the Declara-
tion of Helsinki. For the PAS cohort, the data collected
from patients with a diagnosis of AS can be linked to
other routinely collected datasets using the SAIL system.
To highlight the potential benefits of using the linked
routine data, this paper uses information on healthcare
visits as reported by the AS patients through question-
naires and explores patient pathways in terms of actual
events obtained from the linked GP, OP, IP, and A&E
datasets in the SAIL databank.
Potential benefits of using linked data
The paper attempts to demonstrate the strength of data
linkage in extracting complementary information from
routine sources that are beyond the scope and time hor-
izon of the study data, and does not intend to test
hypotheses with regards to the data quality pertaining to
the specific variable of interest or the individual datasets.
The potential benefits of using linked data are discussed
below.
1. Retrospective and prospective tracking of patient
pathways
With data spanning multiple years and the ability to link
records across several datasets, it is possible using SAIL
to track the healthcare utilisation history of patients in
receipt of some form of intervention for a given condi-
tion across multiple healthcare sectors both before and
after their index/reference healthcare event. Therefore,
the SAIL data linkage system allows tracking of the
patient pathways, both retrospectively and prospectively.
Linkage with GP data system provides information
about patients’ primary care events going back many
years including; previous diagnoses, referrals, presenting
symptoms, investigation results and previous medica-
tions. This dataset can also be used to follow the patient
at every visit to the GP and therefore record the
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medications. Linkage with IP data will record all hospital
visits, surgery and hospital treatment. Linkage with the
mortality datasets will ensure the dataset remains rele-
vant and can examine survival of included patients.
Linkage with A&E datasets will give information on
emergency visits.
2. Validation of patient-reported recall data
The use of linked routine data allows cross-checking of
patient-reported recall data with actual health care
events at the personal level. The inherent limitations (or
strengths) of the data quality pertaining to the survey
questionnaires under the recall method can be flagged;
and an assessment of the generalisability of the patient-
reported data can be made. On the other hand, data
obtained from routinely collected data systems often
require careful interpretation with respect to their qual-
ity, validity, timelines, bias, confounding and statistical
stability [1]. With the triangulation of datasets in the
SAIL system, the validity and reliability of single datasets
can be assessed [6]. The triangulation process will at
least flag the discrepancies, and we can then have an
idea about any quality issue pertaining to both the rou-
tine and questionnaire data. However, this paper does
not intend to make assertions with regards to the data
quality of individual datasets, and views the linking of
datasets primarily as a source of extracting complemen-
tary information which are beyond the scope and time
horizon of traditional study data.
3. Objective measure of the cost of illness
Cost of illness studies are typically subject to a degree of
scrutiny with regards to the sources and methods of
estimating the quantities and prices, the specification of
study perspective, and the identification of the time-
f r a m et ow h i c ht h ec o s t sa p p l y[ 7 - 9 ] .T h eu s eo fl i n k e d
data enhances the precision of the healthcare use infor-
mation and the timelines within which the costs
incurred; and therefore will help provide an objective
estimate of the cost and burden of diseases to the fun-
ders, health service (NHS in the United Kingdom),
society and the individual at each stage of disease over a
prolonged period of time.
In many conditions there is a delay between the onset
of symptoms and establishing a diagnosis, during which
period the patients still utilise healthcare resources. The
linked routine data can provide information about the
patients’ visits to health care facilities during this symp-
tomatic pre-diagnosis period, when the requirement for
diagnostic investigations is often greatest. For example,
within the SAIL data system, using the encrypted ALF,
we can identify patients from a cohort of any particular
disease who were diagnosed during a reference time (as
indicated by first appearance of a specific diagnostic
read code); and link those with various datasets (e.g. GP
data, IP hospital admissions, OP, A&E data etc.) to track
their pre-diagnosis visits to healthcare facilities since the
date the symptom onset (as reported by the patients or
established from the GP or A&E records). This allows
one to compare the extent of health service utilisation,
and therefore related costs, before and after the symp-
toms developed. In addition, one can also calculate the
costs as a result of delayed diagnosis.
The linked healthcare analysis within SAIL need not
be confined to deducing the extent of health service uti-
lisation during the pre- and post-diagnosis illness peri-
ods but can additionally be performed to ascertain the
size of the direct medical costs associated with the index
illness that are incurred across different healthcare sec-
tors. This is possible, for example, with the combined
use of the cost figures included in the Trust Financial
Return 2 (TFR2) accounts [10] that incorporate expendi-
tures relating specifically to A&E attendances, IP admis-
sions and OP contacts; and the cross-sector (i.e. primary
care, secondary care, IP, OP, A&E etc.) health services
utilisation at the individual level obtained from the
linked data system. A system such as the SAIL system
therefore not only allows the index event for a given
condition to be identified but additionally introduces a
longitudinal, temporal, dimension to the analysis as each
of the healthcare sectors captured within SAIL can be
searched for multiple years pre- and post-index health-
care event to determine the extent of health service uti-
lisation and direct medical costs, made possible by the
inclusion of an ALF within all of the SAIL datasets. This
provides a more objective estimate of the actual costs of
chronic conditions and any interventions.
4. Healthcare pathways and referral history
A retrospective analysis of the patient’s healthcare his-
tory can identify the types of referrals to healthcare ser-
vices made at different points in time, thus, giving an
assessment of health service usage and recommenda-
tions for improving patient care pathways. In particular,
the linked GP data would provide important informa-
tion to improve diagnostic and referral pathways, and
thus maximise clinical efficiency and efficiency in the
use of resources. The temporal aspects of the linked
data sets also help conducting event history analysis,
survival analysis and other relevant statistical and econo-
metric models.
5. Profiling of patients
The linked SAIL data includes diverse sets of informa-
tion, which enables profiling and stratification of
patients relating to disease manifestations and severity,
lifestyle, co-morbidities, and associated costs.
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heterogeneous manifestations with a variable course and
unpredictable episodes of exacerbation, the analysis can
be carried out under several person stratification
schemes based on severity of disease, various demo-
graphic attributes, and socio-economic conditions. This
stratification will facilitate early targeting of interven-
tions to patients at highest risk, thereby improving the
cost-effectiveness ratio of these interventions.
Results
An example using a patient with ankylosing spondylitis
Here we present an example of one AS patient’s health
s e r v i c eu s a g eh i s t o r yb yt r a c k i n gt h eh e a l t h c a r ee v e n t s
through the linked datasets and comparing this with
self-reported data. To preserve complete anonymity, the
actual dates are modified by replacing with fictitious
dates. As part of the PAS cohort study, the patient com-
pleted a questionnaire during the first week of Novem-
ber 2009, in which s/he was asked to recall the number
of visits to the GP, OP, IP, A&E, and to various health
professionals during the three months before the ques-
tionnaire completion date. The patient reported 4 GP
visits, 1 OP visit, 1 IP visit, no A&E visit, and visited a
rheumatologist, a radiologist, and a chiropractor once
each. Distances to the healthcare facilities were 1 mile,
3.5 miles, and 3 miles for GP, OP, and IP, respectively.
In each case the patient used their own car; and was
accompanied by someone during the GP and IP visits.
The patient also reported having taken pain reducing
medicines (paracetamol, ibuprofen, and naproxen); hav-
ing undergone an MRI scan and had blood and urine
tests during the 3 months recall period.
Using the unique ALF, we tracked the patient’s health-
care pathways through the routine data in SAIL system.
Figure 1 plots the patient’s healthcare events from the
OP, GP, and A&E datasets for a 2 year period (i.e.
August 2008 to August 2010), which represents the
timeline approximately one year before and one year
after the completion date of the questionnaire by the
patient.
The linked routine data show 10 GP events, 2 OP vis-
its and 1 A&E visit during the 3 month recall period.
There is no IP visit recorded during this period. There-
fore, the self-reported IP visit in the questionnaire may
actually be an A&E visit, which would correlate with the
routine data. Out of those 10 GP events, not all of them
are physical visits by the patients, but may include any
event (e.g. letter encounter, prescription collection, tele-
phone conversation etc.). Further exploration of the GP
read codes and descriptions for these 10 GP events
yields information about medication, tests, and other GP
related encounters, as shown in Table 1. Retrospective
and prospective tracking of events reveals that there are
51 such GP events during the 2 year period (Figure 1).
There are no OP, IP, or A&E visits before or after the
recall period, indicating the danger of extrapolating
patient reported 3 month recall data in the question-
naire over a longer period (e.g. one year). However,
going further back through the linked data system in
terms of the timeline (not shown in the figure), it was
found that the patient made 4 OP visits during August,
October, and November of 2005; and 1 IP visit on the
first week of June 1999.
Examples using the PAS cohort linked to GP data system
Using the GP data we tracked about 183 AS patients
from the PAS cohort retrospectively and prospectively
from the date of questionnaire completion to gather the
following information: (a) number of GP events; (b) pre-
sence of a GP parent family ‘drugs’ read codes; and (c)
the presence of a GP parent family ‘diagnostic’ read
codes.
GP events and visits from the linked routine and
questionnaire data
Table 2 presents the average number of GP events for
the AS patients grouped under several stratification
schemes based on baseline disease severity score (low
and high BASDAI); disease function score (low and high
BASFI); age, sex, and the age of the onset of first symp-
toms. Results are presented for the retrospective 3
months recall period, 1 year period, and 5 years period -
the questionnaire completion dates being the reference
date for each patient. In the last column of Table 2, we
present the self-reported number of GP visits during the
3 month period from the questionnaires. As mentioned
earlier the GP ‘event’ and ‘visits’ are to be construed dif-
ferently. The GP event is defined as the unique dates for
each patient where we can find GP read codes indicat-
ing administrative actions, referrals, visits, telephone
conversation, prescription collection, symptoms, diagno-
sis, prescription drugs etc., pertaining to the particular
patient. The GP visits refer to the physical visits to the
GP by the patient. In the questionnaire the patients
were asked about the visits to the GP. In the presence
of numerous read codes, it is beyond the scope this
paper to identify ‘visits’ from within the ‘events’. Never-
theless, the number of actual visits obtained from the
questionnaire can be used as complementary informa-
tion as to what proportion of the GP events were GP
visits.
Table 2 shows that the patients with low disease
severity have less GP visits and events than the patients
with high disease severity. The patients with low disease
s e v e r i t y ,h a d2 . 8 1 ,1 2 . 9 2 ,a n d6 1 . 9 2e v e n t sr e c o r d e di n
the GP system during the 3 months, 1 year, and 5 year
retrospective period as opposed to 4.25, 17.79, and 80.28
events for the high disease severity groups. These ratios
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Page 4 of 12Figure 1 Healthcare Pathway of an AS Patient. Each shape indicates a separate event (date) captured in the relevant datasets. The X-axis
captures events for a period of two years (i.e. 730 days). Therefore, the GP event markers appear almost overlapped when events occurred in
two consecutive dates (e.g. 31
st August and 1
st September). The questionnaire completion date is 05 November, 2009. The three month patient
recall period is captured by the two vertical dashed lines, indicating the dates 07 August and 05 November. There are 10 GP events during this
time interval, including the overlapped ones.
Table 1 Patient’s GP Read codes during the 3 month recall period
GP Event
Date
(sl) GP Read Codes: Descriptions Comment
10 August (i) fh1k: PREMIQUE 0.625 mg/5 mg tablets; (ii)
b211: BEMDROFLUAZIDE 2.5 mg tablets; (iii) b211: BENDROFLUMETHIAZIDE 2.5 mg
tablets; (iv) bxd2: SIMVASTATIN 20 mg tablets; (v) Bd35: ATENONOL 50 mg tablets
GP visit
/Prescription collection
31 August 1969: Abdominal pain System reporting of A&E admission on 30
August
01
September
Discharge Summary System reporting of A&E discharge summary
(ref: 30 August A&E admission)
17
September
(i) fh1k: PREMIQUE 0.625 mg/5 mg tablets; (ii)
b211: BEMDROFLUAZIDE 2.5 mg tablets; (iii) b211: BENDROFLUMETHIAZIDE 2.5 mg
tablets; (iv) bxd2: SIMVASTATIN 20 mg tablets; (v) Bd35: ATENONOL 50 mg tablets; (vi)
j2ck: NAPROXEN 250 mg e/c tablets; (vii) 246..: O/E blood pressure; (viii) di21:
PARACETAMOL 500 mg; (ix) 8B4: Repeat Prescription.
GP Visit
23
September
(i) 52...: Plain Radiography; (ii) 52....:Plain X-Ray GP visit
07
October
(i) bd35: ATENONOL 50 mg tablets; (ii)
b211: BEMDROFLUAZIDE 2.5 mg tablets; (iii) bxd2: SIMVASTATIN 20 mg tablets; (iv) 8CB..:
Had a chinwag with patient; (v) 8CB..: Had a discussion with patient.
GP visit
11
October
9 N4..: Failed encounter No visit
28
October
(i) b211: BEMDROFLUAZIDE 2.5 mg tablets; (ii) b211: BENDROFLUMETHIAZIDE 2.5 mg
tablets; (iii) bxd2: SIMVASTATIN 20 mg tablets; (iv) Bd35: ATENONOL 50 mg tablets (v)
j2ck: NAPROXEN 250 mg e/c tablets
GP visit/prescription collection
30
October
(i) j2ck: NAPROXEN 25 mg e/c tablets Prescription collection
04
November
(i) 9 N36: Letter from specialist; (ii) Letter from consultant No visit
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reported visits obtained from the questionnaires during
the 3 month recall period, which are 1.31 visits for the
low severity group and 1.78 for the high severity group.
The 3 month GP events and self-reported GP visits in
the high disease severity group were 1.51 and 1.36 times
respectively more than in the low disease severity group
and the between-group relative differences are largely
consistent throughout the 5 year period (see Table 2).
The same strategy can be applied to the other stratifica-
tion models. The data in Table 2 indicates that the lar-
gest discrepancies between self-reported GP visits and
r o u t i n ed a t aG Pe v e n t sa r ei nt h eg r o u p ss t r a t i f i e db y
age and gender. We postulate that this suggests that
older patients with AS (age ≥50) either tend to under-
report GP visits or have more non-visit related GP
events (e.g. for prescriptions) compared to younger
patients, or that the reverse is true for younger patients.
Similar hypotheses can be generated for female and
male patients. This may have important implications as
AS affects men more commonly than women, with
onset in late teens or early adult years.
Linked routine GP data for medications
Table 3 indicates the presence of parent drugs in the AS
patients’ GP history. The GP read codes starting with
small letters a-z indicate the parent drug family the pre-
scribed medicines belong to. Starting with the small let-
ters a-z, the drug related GP read codes extends up to 4
more sub-digits to specifically identify the drug. It is
beyond the scope of this paper to go beyond the first
parent groups. Table 3 shows, in different retrospective
time spans, how many patients’ GP read codes include
the mentioning of a particular drug code at least once.
It is evident that the highest number of patients is pre-
scribed musculoskeletal and joint drugs (read code ‘j’),
followed by the central nervous system drugs (which
Table 2 Number of GP ‘events’ from linked GP data and GP ‘visits’ from questionnaire data
Number of GP ‘events’ from linked GP data (Mean
[95% CI])
Number of GP ‘visits’ from Questionnaire data
Patient Stratification Schemes 5 year period 1 year period 3 month recall
period
3 months recall period
Disease Severity Index
Low (BASDAI < 40)
(n = 72)
61.92
[47.86-75.64]
12.92
[9.96-15.87]
2.81
[2.06-3.55]
1.31
[0.98-1.63]
High (BASDAI > = 40)
(n = 72)
80.28
[64.32-96.23]
17.79
[14.04-21.54]
4.25
[3.22-5.28]
1.78
[1.34-2.21]
Ratio (high/low BASDAI) 1.30 1.38 1.51 1.36
Disease Functional Index
Low (BASFI < 40)
(n = 71)
49.15
[36.99-61.32]
11.20
[8.38-14.02]
2.75
[1.97-3.52]
1.21
[0.87-1.55]
High (BASFI > = 40)
(n = 73)
92.27
[76.34-108.21]
19.40
[15.73-23.07]
4.29
[3.29-5.29]
1.86
[1.45-2.28]
Ratio (high/low BASFI) 1.88 1.73 1.56 1.54
Age
Age < 50
(n = 68)
45.96
[34.05-57.87]
10.46
[7.54-13.38]
2.53
[1.65-3.41]
1.44
[1.00-1.89]
Age > = 50
(n = 76)
93.43
[77.95-108.92]
19.74
[16.27-23.21]
4.42
[3.53-5.31]
1.63
[1.30-1.97]
Ratio (Age > = 50/Age < 40) 2.03 1.89 1.75 1.13
Sex
Male
(n = 113)
75.52
[63.43-87.61]
16.07
[13.32-18.83]
3.69
[2.95-4.43]
1.50
[1.21-1.79]
Female
(n = 31)
54.58
[32.82-76.34]
12.74
[7.82-17.66]
2.93
[1.61-4.26]
1.68
[0.95-2.40]
Ratio (Male/Female) 0.72 0.79 0.79 1.12
Disease Symptom
First Symptom at age < = 30
(n = 112)
66.03
[54.94-77.11]
14.39
[11.86-16.93]
3.29
[2.61-3.98]
1.46
[1.17-1.76]
First Symptom at age > 30
(n = 32)
88.47
[60.53-116.40]
18.72
[12.45-24.99]
4.34
[2.68-6.01]
1.81
[1.11-2.51]
Ratio (first sym. age > 30/age < = 30) 1.34 1.30 1.32 1.24
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recorded in the AS patients include gastro-intestinal sys-
tem drugs (a), cardiovascular system drugs (b),a n dt h e
skin drugs (m), which is consistent with the association
of these diseases with AS. One could go beyond the par-
ent read codes and specifically identify exactly which
drug was prescribed at which date. The drug codes for
the 3 months after (prospective) the dates of baseline
questionnaire completion for 103 AS patients are shown
in the last column of Table 3.
Routine GP data for associated diagnosis
T a b l e4s i m i l a r l ys h o w st h ep r e s e n c eo fp a r e n td i s e a s e
diagnostic read codes (start with capital letters A-Z)i n
the GP data system for the AS patients at 10 years, 5
years, 1 year and 3 months retrospective, and 3 months
prospective time span, relative to the date of question-
naire completion. The most frequent disease group as
indicated by the read codes fall under the musculoskele-
tal/connective tissue (N), skin/subcutaneous tissue dis-
ease (M), nervous system/sense organ diseases (F),
respiratory system disorders (H), digestive system disor-
ders (J), symptoms, signs, ill-defined conditions (R),a n d
infectious/parasitic diseases (A). These are consistent
with the conditions that are associated with AS (e.g. psor-
iasis, uveitis, colitis) or complicate the treatment (e.g.
respiratory infections in patients on immunosuppressive
therapy). Again, further exploration of the parent read
codes by going beyond the first digit would reveal the
specific disease diagnosis.
Examples using the PAS cohort linked to OP and IP data
systems
We tracked 236 and 296 AS patients retrospectively
through the OP and IP data systems respectively to
derive the average number of OP visits and IP admis-
sions made by the patients grouped under different stra-
tification schemes. The results are presented in Table 5.
The table has two panels - columns 1-4 relate to OP
visits, and columns 5-8 relate to the IP admissions.
OP visits
The estimates in columns 3 and 4 of Table 5 report the
average number of visits for the 3 months recall period
obtained from the routine data system and the question-
naires respectively. In principle, the numbers in these
two columns should match as they relate to OP visits
only. It is observed that patients in all groups tend to
overestimate the number of OP visits in the question-
naire. The over-reporting of OP visits is most marked in
those with high disease activity (BASDAI) and func-
tional impairment (BASFI). We postulate that one rea-
son for this may be as a result of these patients finding
it more difficult to physically attend OP clinics due to
Table 3 Presence of Parent Drug & Appliances Read Codes for the AS Patients
Parent
Read Code
Disease Group Retrospective Prospective
10 year
(n = 183)
5 year
(n = 164)
1 year
(n = 147)
3 months
(n = 120)
3 months
(n = 103)
a Gastro-intestinal system drugs 123 103 75 47 42
b Cardiovascular system drugs 69 65 50 39 36
c Respiratory system drugs 74 56 30 18 20
d Central nervous system drugs 147 125 83 52 40
e Drugs for infectious diseases 139 114 59 20 18
f Endocrine drugs 63 56 29 19 13
g Obs/gynae/urinary drugs 42 33 22 8 6
h Malignant & immunosuppr. drug 19 13 9 8 8
i Haematology/dietetic drugs 54 44 29 18 17
j Musculoskeletal & joint drugs 157 134 89 59 52
k Eye drugs 61 48 26 11 9
l Ear, nose & oropharynx drugs 61 48 16 7 6
m Skin drugs 105 90 46 23 17
n Immunology drugs & vaccines 48 38 15 3 0
o Anaesthetics 10 7 1 0 0
p Appliances & reagents etc. 41 37 14 8 8
q Incontinence Appliances 2 2 2 1 1
s Contrast media 8 8 5 3 2
Note: Baseline questionnaire completion is the reference date. The last column applies to the patients whose data in the GP system exist at least 3 months post
questionnaire completion date
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Page 7 of 12their greater disease activity and disability. Again, this
may have important implications when using patient-
reported data to estimate utilisation of healthcare
resources. Figure 2 shows the number of self-reported
and recorded OP visits by the AS patients. The x-axis
shows the number of visits during the 3 months recall
period self-reported in the questionnaire and the y-axis
shows the corresponding number of visits obtained from
the records of OP data. The numbers in the bracket is
the number of patients. For instance, out of 79 patients
who reported in the questionnaire to have visited once
to the OP during the 3 months recall period, we found
29 patients with zero visit, 34 patients with 1 visit, 9
patients with 2 visits, and 7 patients more than 2 visits.
It can be seen that in general, the patients overestimated
the number of OP visits when completing the question-
naires. 29 patients reported an OP visit that was not
recorded during the 3 month recall period, highlighting
issues with using recall data.
IP visits
In the second panel of Table 5 (i.e. columns 5-8), we
tracked 296 AS patients through the IP data system to
obtain the number of IP admissions. Again, in princi-
ple, columns 7 and 8 should match, and indeed these
results for IP admissions are more similar than the
corresponding data for OP visits (columns 3 and 4).
The results in columns 7 and 8 suggest that, in con-
trast to OP visits, patients tend to underestimate the
number of IP visits. Younger patients and those with
less severe disease severity( B A S D A I )a n df u n c t i o n a l
impairment (BASFI) were most likely to underesti-
mate IP admissions. We postulate that this is because
the admission in these patients was more likely to be
for a reason unrelated to their AS, and therefore over-
looked and not reported in a questionnaire for an AS
study.
Tracking through the retrospective data of those who
had at least one IP admission, Table 6 indicates addi-
tional complementary information on the number of
days spent in hospital. This information was not cap-
tured in the questionnaire data. These data indicate that
older patients, those with longer disease duration, higher
disease activity and functional impairment spent signifi-
cantly more days in hospital than their relevant compar-
ison groups. This may also have been a contributory
factor to the relative under-reporting of IP admissions
in patients with lower disease severity or functional
impairment.
Table 4 Presence of Parent Diagnosis Read Codes for the AS Patients
Parent
Read Code
Disease Group Retrospective Prospective
10 year
(n = 183)
5 year
(n = 164)
1 year
(n = 147)
3 months
(n = 120)
3 months
(n = 103)
A Infectious/parasitic diseases 49 35 15 5 1
B Neoplasms 26 16 1 0 0
C Endocr/nutr/metabolic/immun. 42 26 7 0 0
D Blood/blood forming organs 14 9 2 1 1
E Mental disorders 35 26 10 4 0
F Nervous system/sense organ 92 78 25 13 3
G Circulatory system diseases 67 44 6 3 4
H Respiratory system disorders 88 72 25 4 5
J Digestive system disorders 81 47 14 6 7
K Genitourinary system diseases 47 36 8 1 0
L Pregnancy/childbirth/puerperium 1 0 0 0 0
M Skin/subcutaneous tissue diseases 94 77 27 3 6
N Musculoskeletal/connective tissue 149 110 36 9 11
P Congenital anomalies 0 0 0 0 0
Q Perinatal conditions 0 0 0 0 0
R Symptoms, signs, ill-defined conditions 60 48 14 4 4
S Injury and self poisoning 56 31 9 1 2
T Causes of injury/poisoning 21 12 3 0 0
U External causes morbdty/mortlty 2 1 0 0 0
Z Unspecified conditions 29 22 5 3 1
Note: Baseline questionnaire completion is the reference date. The last column applies to the patients whose data in the GP system exist at least 3 months post
questionnaire completion date
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The above examples demonstrate that linked routine
data enables validation and clarification of patient
reported data; the retrospective and prospective tracking
of the patient healthcare utilization and pathways; and
the referral history in a cohort of patients with AS. Such
analysis makes it possible to deduce whether the anon-
ymised individuals in question were suffering any com-
mon co-morbidities, in receipt of healthcare treatment
prior to the occurrence of the reference event, whilst it
also allows any frequent complications requiring medical
attention in the days, months, years following the event
(which could be an intervention or questionnaire) to be
identified. From the methodological perspective, any
linkage system would add new dimensions and perspec-
tive to traditional health related research (e.g. comple-
ment and enhance the results of RCTs), as a resource
for clinical audits, and in a variety of health impact
assessment exercises. For example, the longitudinal rou-
tine data would allow an assessment of the impact of
specific healthcare interventions on subsequent health-
care utilisation (e.g. A&E visits or hospital admission).
Important limitations of solely relying on questionnaire
data include reliance on accurate patient recall and that
Table 5 Number of outpatient (OP) visits and inpatient (IP) admissions from linked and questionnaire data
Number of OP Visits from
linked data
(Mean [95% CI])
# of self-reported OP visits
from Questionnaire
Average Number of IP
admissions from linked
data
(Mean [95% CI])
# of self-reported IP
admissions from
Questionnaire
12 3 4 5 6 7 8
Patient
Stratification
Schemes
5 year 1
year
3 month
recall period
3 months recall period 5
year
1
year
3 month
recall period
3 months recall period
Disease Severity Index
Low (BASDAI <
40)
(n = 119 & 133)
16.78
[13.50-
20.06]
3.84
[2.96-
4.72]
0.87
[0.64-1.09]
1.06
[0.76-1.36]
2.43
[1.38-
3.48]
0.59
[0.26-
0.91]
0.11
[0.05-0.17]
0.08
[0.03-0.13]
High (BASDAI > =
40)
(n = 117 & 163)
21.89
[16.87-
26.91]
6.12
[4.29-
7.95]
1.51
[1.06-1.97]
2.55
[1.54-3.55]
3.01
[2.27-
3.76]
0.74
[0.51-
0.97]
0.17
[0.10-0.23]
0.14
[0.07-0.21]
Disease Functional Index
Low (BASFI < 40)
(n = 110 & 117)
14.17
[11.23-
17.12]
3.05
[2.28-
3.81]
0.73
[0.53-0.93]
0.90
[0.62-1.18]
2.31
[1.06-
3.55]
0.46
[0.12-
0.80]
0.11
[0.05-0.17]
0.05
[0.01-0.09]
High (BASFI > =
40)
(n = 126 & 179)
23.80
[18.93-
28.67]
6.65
[4.92-
8.39]
1.59
[1.16-2.02]
2.58
[1.64-3.52]
3.04
[2.40-
3.69]
0.81
[0.58-
1.04]
0.16
[0.10-0.22]
0.16
[0.09-0.23]
Age
Age < 50
(n = 90 & 164)
18.29
[14.64-
21.94]
5.07
[3.10-
7.03]
1.30
[0.81-1.79]
1.72
[0.80-2.65]
1.91
[1.29-
2.54]
0.49
[0.24-
0.74]
0.16
[0.08-0.25]
0.05
[0.01-0.09]
Age > = 50
(n = 146 & 192)
19.95
[15.65-
24.24]
4.91
[3.79-
6.03]
1.12
[0.84-1.39]
1.84
[1.20-2.48]
3.21
[2.31-
4.11]
0.77
[0.51-
1.04]
0.13
[0.08-0.18]
0.15
[0.08-0.22]
Sex
Male
(n = 183 & 218)
18.20
[14.85-
21.55]
4.35
[3.48-
5.22]
1.02
[0.79-1.25]
1.60
[1.08-2.12]
2.47
[1.96-
2.97]
0.55
[0.40-
0.69]
0.13
[0.08-0.18]
0.10
[0.05-0.15]
Female
(n = 53 & 76)
23.15
[16.50-
29.80]
7.11
[3.71-
10.52]
1.77
[0.98-2.57]
2.47
[0.95-4.00]
3.59
[1.62-
5.57]
1.03
[0.40-
1.66]
0.16
[0.06-0.26]
0.14
[0.05-0.24]
Disease Symptom
First Symptom at
age < = 30
(n = 182 & 226)
19.04
[15.51-
22.57]
4.81
[3.59-
6.04]
1.23
[0.92-1.54]
1.85
[1.20-2.51]
2.38
[1.95-
2.81]
0.58
[0.42-
0.73]
0.14
[0.09-0.19]
0.10
[0.05-0.15]
First Symptom at
age > 30
(n = 54 & 70)
20.22
[14.69-
25.75]
5.50
[3.86-
7.14]
1.04
[0.68-1.40]
1.61
[0.95-2.27]
3.97
[1.71-
6.23]
0.99
[0.33-
1.65]
0.16
[0.05-0.26]
0.17
[0.06-0.28]
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the limited recall period (e.g. 3 months), but just before
the recall period or after the completion date of the
questionnaire. This makes extrapolation of the question-
naire data for an extended period of time unreliable.
The longitudinal linked routine data comes into aid in
this respect.
The linkage of the questionnaire data from the PAS
patients with the GP data as shown above enhances and
helps make sense of the rich information obtained from
the GP Read codes. This constitutes a rich health history
for these AS patients, for whom we can carry out patient
pathway analysis from various clinical and economic
aspects. In particular, in keeping with other AS cohorts,
these patients had an average lag of about 8 years from
symptom onset to AS diagnosis, on which we can conduct
pre- and post-diagnosis analyses of health care utilisation.
Again, a matrix of traits based on the PAS question-
naire information linked with the SAIL data system will
help profiling of AS patients for health and other related
interventions. Table 7 summarises the types of informa-
tion gathered through the PAS questionnaires, which
could all be linked with the routine data sources as well
as various demographic, socio-economic, and environ-
mental attributes of the patients.
The use of HERALD methodology can stratify groups of
patients to identify the early characteristics of patients
who subsequently develop severe disease, thus, enabling
these patients to be targeted with early aggressive therapy
in order to prevent severe damage and need for surgery.
This profiling can be used to estimate the potential
resource savings of focusing treatment on those patients
with patterns of disease suggestive of the development of a
severe outcome. All these will directly affect patient care
for AS in terms of informing NHS service provision and
NICE guidelines for the use of expensive biological thera-
pies, and informing the process of assessment of cost-
effectiveness. In principle, the methods developed for the
PAS cohort and described here can be extrapolated to be
used in other chronic disease conditions [6]; thus improv-
ing patient care for all those conditions. Linked routine
data provides many opportunities for enhanced healthcare
research and allows evaluation of impacts beyond the lim-
ited primary outcomes of interventional studies. As an
example, the expanding SAIL databank in Wales already
holds over a billion anonymised records from various
Figure 2 Outpatient (OP) visits from routine data and self-reported patient recall. Brackets indicate numbers of patients.
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Page 10 of 12databases, which can be anonymously linked at the indivi-
dual record level. The combination of routine data with
information from patients and RCTs allows the validation
of real-life data and its application for clinical research.
These linkable databases provide factual and continuous
information with rich clinical and non-clinical details,
which offers wide ranging opportunities in the realm of
conducting evaluative research, clinical epidemiology, trial
recruitment, genetic research, basic research of biological
markers, stratified medicine, post-trial surveillance, risk
assessment, service delivery evaluation, resource use, deci-
sion analysis, identification of early disease predictors, and
Table 6 Inpatient (IP) Spells: Average Number of days as IP from Linked IP data
Patient Stratification Schemes Average Number of days as IP from Linked IP data
(Mean [# attended][95% CI])
5 years 1 year 3 months recall period
Disease Severity Index
Low (BASDAI < 40) 10.82
[n = 100] [7.48-14.16]
5.06
[n = 36] [3.04-7.07]
1.43
[n = 14] [0.94-1.92]
High (BASDAI > = 40) 12.97
[118] [9.16-16.79]
5.62
[58] [3.87-7.37]
2.33
[24] [1.02-3.64]
Disease Functional Index
Low (BASFI < 40) 9.31
[81] [6.03-12.59]
4.04
[25] [1.51-6.57]
1.25
[12] [0.96-1.54]
High (BASFI > = 40) 13.57
[137] [9.99-17.15]
5.90
[69] [4.36-7.44]
2.35
[26] [1.13-3.56]
Age
Age < 50 7.11
[75] [4.74-9.48]
3.37
[30] [1.75-4.98]
1.4
[15] [0.94-1.86]
Age > = 50 14.55
[143] [10.90-18.19]
6.36
[64] [4.63-8.09]
2.39
[23] [1.03-3.75]
Sex
Male 12.13
[158] [9.22-15.04]
4.93
[69] [3.47-6.38]
2.00
[27] [0.90-3.10]
Female 11.72
[58] [6.14-17.31]
6.83
[24] [3.79-9.87]
2.00
[10] [0.57-3.43]
Disease Symptom
First Symptom at age < = 30 10.96
[170] [8.14-13.77]
4.65
[75] [3.31-6.00]
1.38
[29] [1.12-1.64]
First Symptom at age > 30 15.63
[48] [9.59-21.66]
8.37
[19] [4.76-11.98]
4.00
[9] [0.37-7.63]
Table 7 PAS Questionnaire Contents
Questionnaire
(Time Interval)
Summary of Information
Baseline
(0)
Co-morbidities, family history, age of diagnosis and first symptoms, disease activity [11], function [12], Quality of life (EQ-5D) [13],
and visits to health professionals
Not at work
(3 Months)
Previous occupation, activity impairment questionnaire
At work
(3 months)
Work questionnaire, including information about current and previous occupation, activity impairment and work limitations
questionnaire (WLQ) [14], work productivity and activity impairment questionnaire (WPAI-SHP) [15,16]
AS costs
(9 months)
AS Cost questionnaire including detailed patient-level information about visits to health care facilities, professionals, AS related
pathology and other tests, other conditions, medications, costs of various aspects of treatment and disability
Exercise and
Fatigue
(15 months)
International Physical Activity Questionnaire (IPAQ) [17], disease activity, function, Behavioural Regulation in Exercise
Questionnaire (BREQ-2) [18], Pittsburgh Sleep Quality Index [19], and the Hospital Anxiety and Depression Scale [20,21])
Medication
(0,3,6,9,12,15
Months)
Medication
Legend: AS patients in the PAS cohort were asked to consent to completing questionnaires either online if they have internet access, or by post. A website has
been developed to give access to the questionnaires http://www.ashealth.co.uk/
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Page 11 of 12the identification of subjects for prospective studies
[6,22,23]. This data system also offers the opportunity for
post-marketing surveillance and pharmacovigilance of new
expensive, and often potentially dangerous, healthcare
interventions in real-life settings. Complementing this
resource with targeted health economic analysis, as pro-
posed in the HERALD methodology, offers a unique
opportunity to deliver the level of health economic data
required to evaluate and drive forward cost-effective mod-
ern healthcare services.
Conclusion
The linkage of routine data, patient completed question-
naires and trial data offers unique opportunities for
enhanced health economic analysis, including assess-
ment of the validity, reliability and generalisability of
health economic data not possible through the use of
traditional isolated datasets. The information obtained
from the linked data system would help improving
patient pathways, and thus maximise clinical efficiency
and efficiency in the use of resources.
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